Publications
Detailed Information
Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Jin Seok | - |
dc.contributor.author | Ahn, Yong Chan | - |
dc.contributor.author | Kim, Joo-Hang | - |
dc.contributor.author | Lee, Chang Geol | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Lee, Kyu Chan | - |
dc.contributor.author | Chen, Ming | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Hoon-Kyo | - |
dc.contributor.author | Min, Young Joo | - |
dc.contributor.author | Kang, Jin-Hyoung | - |
dc.contributor.author | Choi, Jin-Hyuck | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Zhu, Guangying | - |
dc.contributor.author | Wu, Yi-Long | - |
dc.contributor.author | Kim, Sung Rok | - |
dc.contributor.author | Lee, Kyung Hee | - |
dc.contributor.author | Song, Hong Suk | - |
dc.contributor.author | Choi, Yoon-La | - |
dc.contributor.author | Sun, Jong-Mu | - |
dc.contributor.author | Jung, Sin-Ho | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.contributor.author | Park, Keunchil | - |
dc.date.accessioned | 2020-04-27T11:20:37Z | - |
dc.date.available | 2020-04-27T11:20:37Z | - |
dc.date.created | 2018-11-01 | - |
dc.date.issued | 2015-08 | - |
dc.identifier.citation | Journal of Clinical Oncology, Vol.33 No.24, pp.2660-2666 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.other | 65076 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165368 | - |
dc.description.abstract | Purpose To determine the efficacy of consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents in locally advanced non-small-cell lung cancer (LA-NSCLC). Patient and Methods Patients were randomly assigned to either CCRT alone (observation arm) or CCRT followed by CC (consolidation arm). CCRT with docetaxel (20 mg/m(2)) and cisplatin (20 mg/m(2)) was administered every week for 6 weeks with a total dose of 66 Gy of thoracic radiotherapy in 33 fractions. In the consolidation arm, patients were further treated with three cycles of DP (35 mg/m(2) each on days 1 and 8, every 3 weeks). The primary end point was 40% improvement in progression-free survival (PFS) compared with observation. Results From October 2005 to April 2011, 437 patients were randomly assigned. Seventeen patients did not start CCRT as a result of consent withdrawal or ineligibility reasons after random assignment, leaving 420 patients for this analysis (n = 211 for observation; n = 209 for consolidation). Patient characteristics were similar in both arms. In the consolidation arm, 143 patients (68%) received CC, of whom 88 (62%) completed three planned cycles. The median PFS was 8.1 months in the observation arm and 9.1 months in the consolidation arm (hazard ratio, 0.91; 95% CI, 0.73 to 1.12; P = .36). Median overall survival times were 20.6 and 21.8 months in the observation and consolidation arms, respectively (HR, 0.91; 95% CI, 0.72 to 1.25; P = .44). Conclusion CC with DP after CCRT with weekly DP in LA-NSCLC failed to further prolong PFS. CCRT alone should remain the standard of care. (C) 2015 by American Society of Clinical Oncology | - |
dc.language | 영어 | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.title | Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04 | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1200/JCO.2014.60.0130 | - |
dc.citation.journaltitle | Journal of Clinical Oncology | - |
dc.identifier.wosid | 000361655000015 | - |
dc.identifier.scopusid | 2-s2.0-84940484434 | - |
dc.citation.endpage | 2666 | - |
dc.citation.number | 24 | - |
dc.citation.startpage | 2660 | - |
dc.citation.volume | 33 | - |
dc.identifier.sci | 000361655000015 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | HYPERFRACTIONATED RADIATION-THERAPY | - |
dc.subject.keywordPlus | BETA-TUBULIN EXPRESSION | - |
dc.subject.keywordPlus | THORACIC RADIOTHERAPY | - |
dc.subject.keywordPlus | 2ND-LINE CHEMOTHERAPY | - |
dc.subject.keywordPlus | DNA-REPAIR | - |
dc.subject.keywordPlus | ERCC1 | - |
dc.subject.keywordPlus | CHEMORADIOTHERAPY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | ETOPOSIDE | - |
dc.subject.keywordPlus | SURVIVAL | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.